Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
Linde
R
R
Children's Hospital, Wolgang Goethe-University Frankfurt, Germany.
Funk
M B
MB
Schuster
T
T
Wintergerst
U
U
Notheis
G
G
Klingebiel
T
T
Kreuz
W
W
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000235:genetics*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics / Q000254:growth & development; D006801:Humans; D019469:Indinavir / Q000627:therapeutic use; D007223:Infant; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D019888:Nelfinavir / Q000627:therapeutic use; D010641:Phenotype; D017354:Point Mutation; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use; D013995:Time; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D054303:HIV Reverse Transcriptase; D019888:Nelfinavir; D019438:Ritonavir